Vertex Pharmaceuticals has caught investors’ eyes, but its stock performance isn’t exactly a mic-drop moment. Despite massive ...

Medical experts emphasized the importance of considering different patient needs when deciding which treatments to employ for pain management at a May 29 Axios event. Axios' Maya Goldman and Erica ...

Explore the future of the pharmaceutical industry with this comprehensive report. Delve into key trends via regulatory, clinical, and market analyses. Essential for investors, new entrants, and pharma ...

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Vertex Pharmaceuticals's VRTX short percent of float has risen 27.71% since its last report. The company recently reported ...

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

CRISPR Therapeutics CRSP is currently the only company in the world to have secured approval for a CRISPR-based gene therapy ...

Eli Lilly's portfolio, both within and outside its core area, makes the stock attractive. However, a recent move Eli Lilly made reveals an underrated reason why the stock has attractive prospects.